HairDAO (CRYPTO: HAIR) — Company Overview, News & Financial Data
HairDAO is an open-source research and development network where patients, community members, and researchers collaborate to develop novel treatments for hair loss.
HairDAO
About
HairDAO is an open-source research and development network where patients, community members, and researchers collaborate to develop novel treatments for hair loss. The organization operates a decentralized ecosystem designed to address early-stage hair loss R&D funding shortages by pooling capital and crowdsourcing research proposals. Token holders govern the network by voting on research grants, clinical studies, and intellectual property strategies. HairDAO funds preclinical studies, files patent applications for topical formulations, and enables patients to log treatment progress anonymously. By combining open-source data collection with community-directed funding, the platform seeks to discover and advance scalable therapeutic solutions for androgenetic alopecia.
Snapshot
Operations
Products and/or services of HairDAO
- Research Funding and Governance Platform: A decentralized voting network powered by governance tokens where researchers propose early-stage hair loss studies and community members vote on capital allocation, drug discovery initiatives, and intellectual property acquisition strategies.
- Patient Data Logging Application: A patient-centric platform allowing individuals anonymously to log treatment progress, track therapeutic regimens, and submit clinical experience data to support research projects while earning protocol rewards for data contributions.
- Topical Hormone Regimen R&D: Early-stage research and patent-pending topical formulation projects involving Thyrotropin-releasing Hormone (TRH), Liothyronine (T3), and Levothyroxine (T4) aimed at stimulating human hair follicle growth and scalp tissue regeneration ex vivo.
- Repurposed Small Molecule Research: Early-stage drug discovery programs developing proprietary topical delivery systems for repurposed FDA-approved molecules—including Naltrexone, Olanzapine, Doxycycline, and Farnesol—to evaluate hair regrowth effects in human hair follicles ex vivo.
- Protein Target and Cell Line Studies: Preclinical research programs focusing on Twist-1 protein inhibition in human dermal papilla cells and YAP-1 inhibition aimed at enabling scarless hair transplantation through clinical partner collaborations.
- Topical Delivery Vehicle Research: A funded drug optimization program dedicated to developing novel topical delivery mechanisms for Dutasteride, aiming to retain therapeutic efficacy against hair loss while reducing systemic absorption and adverse side effects.